In a call hosted recently, Nasus Pharma (NYSE:NSRX) presented strong positive topline results from its Phase 2 clinical study ...
KORU Medical Systems, Inc. (NASDAQ:KRMD) Q4 2025 Earnings Call Transcript March 12, 2026 KORU Medical Systems, Inc. beats earnings expectations. Reported EPS is $-0.01, expectations were $-0.02.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results